Names like Yuhan, Chong Kun Dang, and Celltrion are what consumers see, but the real strength of the pharmaceutical industry comes from the processes and validation running behind the scenes. APIs that form the backbone of a drug, CDMOs that manufacture someone else’s pipeline, and CROs that build the data needed before and after human use. A single new drug has low odds of success and high volatility. But this side of the industry is a bit different. No matter who succeeds in development, they still need raw ingredients, manufacturing facilities, and data to clear clinical trials and regulatory approval. The saying that selling picks is more stable than mining for gold is often true in pharma.
On top of that, this is not an industry where anyone can walk in and win just by offering a lower price. You need accumulated GMP and GLP capabilities, a regulatory track record, and experience handling audits and inspections. That is why, once a business relationship is established, it is not easy to switch. Of course, there is no room for fantasy. In APIs, low-cost competition from China and India is always there, and CROs find it hard to avoid dependence in relationships with large global players. Even so, there is a clear reason to revisit this back end of the industry now. The U.S. Biosecure Act issue is driving caution toward Chinese CDMOs, and next-generation modalities such as oligos and peptides are difficult to manufacture, creating bigger opportunities for Korean companies. When the board is reset, the companies that have been holding the line in the background are often the first to come into view.
Active Pharmaceutical Ingredients (API) — Making the Raw Materials for Medicines (4 companies)
APIs may not be highly visible, but they are the starting point of every drug—and the value of a domestic supply chain tends to be priced much higher in times of crisis.
The character of this segment is fairly clear. Kyongbo Pharmaceutical is a leading domestic player in cephalosporin antibiotic APIs, and given its affiliation with Chong Kun Dang, it is best understood as a key pillar in the antibiotic raw-materials chain. Chong Kun Dang Bio has built its base on antibiotic products such as clavulanate K and acarbose APIs, while expanding its portfolio into probiotics and botulinum toxin. Hwail Pharmaceutical has a well-defined identity as a specialist in synthetic APIs, while also diversifying into cephalosporin finished drugs and functional food ingredients. Daebong LS combines amino acid-based APIs such as NAC and erdosteine with cosmetic ingredients, and its surpassing KRW 100 billion in sales in 2025 shows a clear step-up in scale. Still, let’s be blunt. APIs are, by nature, under intense pricing pressure. Against low-cost competition from China and India, it is not easy to hold the line with only commoditized bulk ingredients. That is exactly why defenses such as antibiotics, amino acid-based ingredients, captive group demand, and diversification matter so much. Making raw materials is not simple subcontracting—it is a business of selling supply stability and a proven quality track record. The market does not always reward that value generously, but every time the supply chain is shaken, it gets recognized again.
| Company | Core focus |
|---|
| Kyongbo Pharmaceutical | Leading domestic cephalosporin antibiotic API player — affiliated with Chong Kun Dang |
| Chong Kun Dang Bio | Antibiotics (clavulanate K) and acarbose APIs + probiotics and botulinum toxin |
| Hwail Pharmaceutical | Specialist in synthetic APIs — diversified into cephalosporin finished drugs and functional food ingredients |
| Daebong LS | Amino acid-based APIs (NAC, erdosteine) + cosmetic ingredients (surpassed KRW 100 billion in 2025 sales) |
Oligo & Bio CDMO — Next-Generation Contract Manufacturing (2 companies)
Oligo and bio CDMOs are not some peripheral play on the new-drug theme—they are much closer to the core battleground where earnings show up first in the era of next-generation modalities.
The most emblematic company here is ST Pharm. It is Asia’s No. 1 oligonucleotide CDMO and a global top-tier player, with small-molecule APIs on top of that. Its affiliation with the Dong-A Socio Group adds another layer of credibility. If you ask why a company like ST Pharm is structurally positioned to grow right now, the answer is simple: next-generation modalities such as oligos are hard to manufacture, and there are not many proven production partners. As the push to check Chinese CDMOs strengthens amid the U.S. Biosecure Act issue, Korean players could see spillover benefits. Binex is also hard to ignore. It operates in both biopharmaceutical CDMO and synthetic pharmaceuticals, and its 2025 FDA cGMP clearance laid the groundwork for expanding commercial production. Manufacturing is ultimately a trust game. Clients only hand over projects when a company has passed audits, built commercial production experience, and established a reliable quality system. That said, this is not a space to view through rose-colored glasses alone. CDMOs are affected by their clients’ development success and order volumes. But that is exactly why the stronger companies survive. In a new-drug race where no one knows which candidate will win, the side taking on multiple clients’ pipelines at once is actually spreading its risk. It is a very different proposition from betting on a single drug.
| Company | Core strength |
|---|
| ST Pharm | Asia’s No. 1 oligonucleotide CDMO and a global top-tier player + small-molecule APIs — affiliated with Dong-A Socio Group |
| Binex | Biopharmaceutical CDMO + synthetic pharmaceuticals — expanding commercial production following 2025 FDA cGMP clearance |
CRO — Validating Drug Development on Developers’ Behalf (4 companies)
CROs are a business that grows alongside drug-development booms, and even when plenty of projects fail, demand for validation itself does not disappear.
Korea’s CRO players also have clearly defined roles. DTCRO is a full-service CRO covering nonclinical safety and toxicology, clinical trials, and regulatory approval. Combined with its affiliation with the DT&C group, it reads as a model that helps developers cut time and communication costs. Biotoxtech is a nonclinical CRO, with toxicology assessment and GLP at its core, and it has passed FDA and OECD inspections. That track record is not just a marketing line. It is proof of credibility in a regulated environment. C&R Research, founded in 1997, was Korea’s first CRO and specializes in clinical trial outsourcing and operations. DreamCIS is a clinical CRO handling the full cycle of clinical data and statistics, and what stands out is that it was the first CRO listed on KOSDAQ, with Tigermed as its largest shareholder. That said, this industry has its weak points too. In relationships with large global players, a certain degree of dependence is unavoidable, and the clinical-order environment is affected by the economy and investor sentiment. Even so, the core logic is clear. The more developers there are, the more testing gets done, and the more testing there is, the more companies are needed to handle the data. Just because the success rate for new drugs is low, does CRO work disappear? If anything, even the process of filtering out failures becomes part of the job.
| Company | Core focus |
|---|
| DTCRO | Full-service CRO for nonclinical (safety/toxicology) + clinical + regulatory approval — part of the DT&C group |
| Biotoxtech | Nonclinical CRO (toxicology assessment, GLP) — passed FDA/OECD inspections |
| C&R Research | Clinical CRO (clinical trial outsourcing and operations) — founded in 1997 as Korea’s first CRO |
| DreamCIS | Clinical CRO (full-cycle clinical data and statistics) — first CRO listed on KOSDAQ, largest shareholder Tigermed |
What to Watch Going Forward
The picture ahead is likely to become much clearer. The U.S. Biosecure Act issue is not just another headline—it is a signal of supply chain realignment. If growing caution toward Chinese CDMOs actually leads to a shift in orders, Korean CDMO and API companies could enjoy a longer-than-expected period of spillover benefits. And as next-generation modalities such as oligos and peptides continue to grow, the value of manufacturing complexity and quality track records will rise even further. That is exactly why companies like ST Pharm keep getting called up by the market. New drug headlines are always flashy, but in the real industry, the money is usually made more steadily in less glamorous places.
That said, I am not arguing that everything will automatically get better. APIs still have to face direct low-cost pressure from China and India, and CROs may have limited bargaining power within the value chains of large global players. In the end, the companies that survive are fairly obvious: those with established regulatory track records, high process complexity, and positions that customers cannot easily replace. There is a reason people talk about hidden champions behind the big brands. If you look at the pharmaceutical industry by chasing only drug candidates, you are seeing only half the picture. No matter who makes the drug or who runs the clinical trials, there are always companies behind the scenes supporting the entire ecosystem. Frankly, I see that side as the more realistic one.
※ This article organizes company names, core businesses, and market positions based on publicly available materials verified on the web, and some assessments reflect the author’s personal views. It is not intended as a direct basis for investment decisions.
Written: July 2026. Ealexandro
댓글
댓글 쓰기